Ablative and catheter-directed therapies for colorectal liver and lung metastases

Hematology/Oncology Clinics of North America

Volumn 29, Issue 1, 2015, Pages 117-133

  Petre, Elena N ^a   Sofocleous, Constantinos T ^a   Solomon, Stephen B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ablation therapy; Colorectal liver metastases; Colorectal lung metastases; Interventional radiology; Intra arterial therapy

Indexed keywords

ABLATION THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATHETER ABLATION; CHEMOEMBOLIZATION; COLORECTAL LIVER METASTASIS; COLORECTAL LUNG METASTASIS; ELECTROPORATION; HUMAN; LONG TERM SURVIVAL; LUNG METASTASIS; MICROWAVE THERAPY; REVIEW; COLORECTAL TUMOR; LIVER NEOPLASMS; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

CATHETER ABLATION; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84919387065     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.09.007     Document Type: Review

References (100)

1. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47(1):82-89.
2. Garden O.J., Rees M., Poston G.J., et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006, 55(Suppl 3):iii1-iii8.
3. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. [discussion: 318-21].
4. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235(6):759-766.
5. Goldberg R.M., Sargent D.J., Morton R.F., et al. Arandomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. JClin Oncol 2004, 22(1):23-30.
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004, 350(23):2335-2342.
7. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370(9582):143-152.
8. Pathak S., Jones R., Tang J.M., et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 2011, 13(9):e252-e265.
9. Umeda Y., Matsuda H., Sadamori H., et al. Aprognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection. World J Surg 2011, 35(1):170-177.
10. Sofocleous C.T., Petre E.N., Gonen M., et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. JVasc Interv Radiol 2011, 22(6):755-761.
11. Erinjeri J.P., Fong A.J., Kemeny N.E., et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011, 117(6):1296-1301.
12. Sofocleous C.T., Nascimento R.G., Petrovic L.M., et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology 2008, 249(1):364-374.
13. Solbiati L., Livraghi T., Goldberg S.N., et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001, 221(1):159-166.
14. Gillams A.R., Lees W.R. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004, 14(12):2261-2267.
15. White T.J., Roy-Choudhury S.H., Breen D.J., et al. Percutaneous radiofrequency ablation of colorectal hepatic metastases - initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg 2004, 21(4):314-320.
16. Feliberti E.C., Wagman L.D. Radiofrequency ablation of liver metastases from colorectal carcinoma. Cancer Control 2006, 13(1):48-51.
17. Hur H., Ko Y.T., Min B.S., et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009, 197(6):728-736.
18. Otto G., Duber C., Hoppe-Lotichius M., et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010, 251(5):796-803.
19. Solbiati L., Ahmed M., Cova L., et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012, 265(3):958-968.
20. Oshowo A., Gillams A., Harrison E., et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003, 90(10):1240-1243.
21. Park I.J., Kim H.C., Yu C.S., et al. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008, 15(1):227-232.
22. White R., Avital I., Sofocleous C., et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. JGastrointest Surg 2007, 11(3):256-263.
23. Berber E., Tsinberg M., Tellioglu G., et al. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. JGastrointest Surg 2008, 12(11):1967-1972.
24. Gleisner A.L., Choti M.A., Assumpcao L., et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008, 143(12):1204-1212.
25. Kim K.H., Yoon Y.S., Yu C.S., et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. JKorean Surg Soc 2011, 81(1):25-34.
26. Mulier S., Ruers T., Jamart J., et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update. Dig Surg 2008, 25(6):445-460.
27. de Baere T., Elias D., Dromain C., et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000, 175(6):1619-1625.
28. Berber E., Pelley R., Siperstein A.E. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. JClin Oncol 2005, 23(7):1358-1364.
29. Ruers T., Punt C., Van Coevorden F., et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012, 23(10):2619-2626.
30. Pawlik T.M., Tanabe K.K. Radiofrequency ablation for primary and metastatic liver tumors. Cancer Treat Res 2001, 109:247-267.
31. Kuvshinoff B.W., Ota D.M. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002, 132(4):605-611. [discussion: 611-2].
32. Kei S.K., Rhim H., Choi D., et al. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol 2008, 190(6):1544-1551.
33. Rossi S., Garbagnati F., Lencioni R., et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000, 217(1):119-126.
34. Mulier S., Ni Y., Jamart J., et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008, 15(1):144-157.
35. Livraghi T., Solbiati L., Meloni F., et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer 2003, 97(12):3027-3035.
36. Kim Y.S., Rhim H., Cho O.K., et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006, 59(3):432-441.
37. Ayav A., Germain A., Marchal F., et al. Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg 2010, 200(4):435-439.
38. Mulier S., Ni Y., Jamart J., et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg Oncol 2005, 242:158-171.
39. Nakazawa T., Kokubu S., Shibuya A., et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007, 188(2):480-488.
40. Lu D.S., Raman S.S., Limanond P., et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. JVasc Interv Radiol 2003, 14(10):1267-1274.
41. de Jong M.C., Pulitano C., Ribero D., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250(3):440-448.
42. Kim Y.S., Lee W.J., Rhim H., et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 2010, 195(3):758-765.
43. Liu C.H., Arellano R.S., Uppot R.N., et al. Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur Radiol 2010, 20(4):877-885.
44. Wang X., Sofocleous C.T., Erinjeri J.P., et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2012, 36:166-175.
45. Seifert J.K., Springer A., Baier P., et al. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. Int J Colorectal Dis 2005, 20(6):507-520.
46. Niu R., Yan T.D., Zhu J.C., et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol 2007, 14(7):2078-2087.
47. Ng K.M., Chua T.C., Saxena A., et al. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol 2012, 19(4):1276-1283.
48. Groeschl R.T., Pilgrim C.H., Hanna E.M., et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2013, 259:1195-1200.
49. Tanaka K., Shimada H., Nagano Y., et al. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery 2006, 139(2):263-273.
50. Ogata Y., Uchida S., Hisaka T., et al. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. Hepatogastroenterology 2008, 55(82-83):550-556.
51. Shibata T., Niinobu T., Ogata N., et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000, 89(2):276-284.
52. Cannon R., Ellis S., Hayes D., et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. JSurg Oncol 2013, 107(5):544-549.
53. Thomson K.R., Cheung W., Ellis S.J., et al. Investigation of the safety of irreversible electroporation in humans. JVasc Interv Radiol 2011, 22(5):611-621.
54. Silk M.T., Wimmer T., Lee K.S., et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. JVasc Interv Radiol 2014, 25(1):112-118.
55. Kingham T.P., Karkar A.M., D'Angelica M.I., et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. JAm Coll Surg 2012, 215(3):379-387.
56. de Baere T., Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging 2011, 36(6):661-670.
57. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. JClin Oncol 2009, 27(21):3465-3471.
58. Cohen A.D., Kemeny N.E. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003, 8(6):553-566.
59. Kemeny M. Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. Cancer J 2002, 8(Suppl 1):S82-S88.
60. Ganeshan A., Upponi S., Hon L.Q., et al. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008, 19(5):847-851.
61. Nakakuma K., Tashiro S., Hiraoka T., et al. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985, 154(1):15-17.
62. Konno T., Maeda H., Iwai K., et al. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984, 54(11):2367-2374.
63. de Baere T., Dufaux J., Roche A., et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 1995, 194(1):165-170.
64. Egawa H., Maki A., Mori K., et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. JSurg Oncol 1990, 44(2):109-114.
65. Kruskal J.B., Hlatky L., Hahnfeldt P., et al. Invivo and invitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. JVasc Interv Radiol 1993, 4(6):741-747.
66. Albert M., Kiefer M.V., Sun W., et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011, 117(2):343-352.
67. Vogl T.J., Gruber T., Balzer J.O., et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009, 250(1):281-289.
68. Taylor R.R., Tang Y., Gonzalez M.V., et al. Irinotecan drug eluting beads for use in chemoembolization: invitro and invivo evaluation of drug release properties. Eur J Pharm Sci 2007, 30(1):7-14.
69. Fiorentini G., Aliberti C., Tilli M., et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012, 32(4):1387-1395.
70. Martin R.C., Joshi J., Robbins K., et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011, 18(1):192-198.
71. Hong K., McBride J.D., Georgiades C.S., et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. JVasc Interv Radiol 2009, 20(3):360-367.
72. Martin R.C., Howard J., Tomalty D., et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010, 33(5):960-966.
73. Russell A.H., Clyde C., Wasserman T.H., et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993, 27(1):117-123.
74. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21(1):109-122.
75. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. JClin Oncol 2000, 18(11):2210-2218.
76. Kennedy A.S., Nutting C., Coldwell D., et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004, 60(5):1552-1563.
77. Sofocleous C.T., Garcia A.R., Pandit-Taskar N., et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer 2013, 13:27-36.
78. 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006, 65(2):412-425.
79. Jakobs T.F., Hoffmann R.T., Dehm K., et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. JVasc Interv Radiol 2008, 19(8):1187-1195.
80. Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19(4):951-959.
81. Cosimelli M., Golfieri R., Cagol P.P., et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010, 103(3):324-331.
82. Van Hazel G., Blackwell A., Anderson J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. JSurg Oncol 2004, 88(2):78-85.
83. Hendlisz A., Van den Eynde M., Peeters M., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. JClin Oncol 2010, 28(23):3687-3694.
84. Nicolay N.H., Berry D.P., Sharma R.A. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009, 6(12):687-697.
85. Watanabe K., Nagai K., Kobayashi A., et al. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009, 96(9):1058-1065.
86. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. JThorac Cardiovasc Surg 1997, 113(1):37-49.
87. Mori M., Tomoda H., Ishida T., et al. Surgical resection of pulmonary metastases from colorectal adenocarcinoma. Special reference to repeated pulmonary resections. Arch Surg 1991, 126(10):1297-1301. [discussion: 1302].
88. Saito Y., Omiya H., Kohno K., et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. JThorac Cardiovasc Surg 2002, 124(5):1007-1013.
89. Li W.H., Peng J.J., Xiang J.Q., et al. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol 2010, 16(26):3318-3324.
90. Lencioni R., Crocetti L., Cioni R., et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008, 9(7):621-628.
91. Yan T.D., King J., Sjarif A., et al. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol 2007, 14(5):1718-1726.
92. Yamakado K., Hase S., Matsuoka T., et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. JVasc Interv Radiol 2007, 18(3):393-398.
93. Hiraki T., Gobara H., Iishi T., et al. Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: midterm results in 27 patients. JVasc Interv Radiol 2007, 18(10):1264-1269.
94. Petre E.N., Jia X., Thornton R.H., et al. Treatment of pulmonary colorectal metastases by radiofrequency ablation. Clin Colorectal Cancer 2013, 12(1):37-44.
95. Gillams A., Khan Z., Osborn P., et al. Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 2013, 36(3):724-730.
96. Yamakado K., Inoue Y., Takao M., et al. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep 2009, 22(4):885-891.
97. Vogl T.J., Naguib N.N., Gruber-Rouh T., et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology 2011, 261(2):643-651.
98. Khuri S.F., Henderson W.G., DePalma R.G., et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005, 242(3):326-341. [discussion: 341-3].
99. Hiromichi I., Chandrakanth A., Gonen M., et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic CRC. Ann Surg 2008, 247(6):994-1002.
100. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12(12):1711-1720.